Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

TACT411

Add links
From Wikipedia, the free encyclopedia

TACT411
Clinical data
Other namesTACT-411
Drug classMonoamine transporter modulator; Serotonin 5-HT1B receptor modulator

TACT411 is a monoamine transporter modulator and serotonin 5-HT1B receptor modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder.[1][2] It is being developed by Tactogen.[1][2] As of the first quarter of 2025, the drug is in the preclinical research stage of development.[1][2] The exact chemical structure of TACT411 does not yet appear to have been disclosed, but it may be a substituted benzofuran derivative.[3]

See also

[edit]

References

[edit]
  1. 1 2 3 Haichin M (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.
  2. 1 2 3 "Tactogen Inc – Pipeline". Tactogen Inc. Retrieved 29 January 2025. OUR PIPELINE: [...] COMPOUND: TACT411/833*. TARGETS: 5-HT1B & MATs. INDICATION: Alcohol Use Disorder. Prevalence: 13.9%. STATUS: Preclinical. COMPOUND: TACT411/833*. TARGETS: 5-HT1B & MATs. INDICATION: Anorexia / Binge Eating Disorder. Prevalence: 3.6%. STATUS: Preclinical. [...] *We will make a final decision among our lead candidates after completing IND-enabling studies. Alternate lead candidates include TACT 523.
  3. ↑ US 20230150963, Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", published 2023 May 18, assigned to Tactogen
Retrieved from "https://en.wikipedia.org/w/index.php?title=TACT411&oldid=1359996736"